Philip Saylor MD, is a genitourinary medical oncologist and clinical/translational investigator at the MGB Cancer Institute, where he has been an attending physician since 2010. His in-person clinics are located on the MGH Boston campus in the Yawkey building (Yawkey 7E clinic area) and at the MGB Healthcare Center in Waltham. He also provides virtual care for patients in Massachusetts, New Hampshire, Maine, and Rhode Island. He and his team provide collaborative care for patients with genitourinary cancers (prostate, kidney/renal cell, bladder & upper tract urothelial, testicular, and adrenal cancers). His practice is primarily based in the outpatient clinic, but he also works approximately 1 month per year providing hospital-based care. 

His research focuses on prostate cancer and other genitourinary cancers with emphasis on (1) team-oriented bedside-to-bench collaboration to better understand the biology of the tumor microenvironment, and (2) the metabolic side effects of systemic prostate cancer treatments. Among other efforts, he has worked since 2016 with a diverse coalition of collaborators (clinically skilled physician investigators from a variety of disciplines, lab investigators focused on tumor biology & bio-orthogonal chemistry, and bio-informatics experts) to study human bone metastasis tissue at the single cell level. It is his belief that this sort of low ego / team-oriented research can accomplish things that wouldn't be possible for any smaller sub-set of the people involved. Improving the lives of patients is the ultimate goal and inspiration for all of this work.

Dr. Saylor is originally from the San Francisco Bay Area. He earned his MD from the University of Pittsburgh School of Medicine, then completed his internal medicine residency at the University of California San Diego. His fellowship in medical oncology brought him to Massachusetts for training at the Dana Farber Cancer Institute and MGH.